Each ml Vometa Drops contains:
Domperidone 5 mg
Domperidone is a benzimidazole derivative with prokinetic and antiemetic effects. Domperidone is an antidopaminergic which has a similar to metoclopramide. Extrapyramidal reactions are rare as Domperidone does not cross the blood brain barrier. Oral or IV administration prolongs the contraction of anthrum and duodenum, increase gastric emptying and pressure of lower oesophagus sphincter. There is no side effect to gastric secretion.
Nausea, vomiting and dyspepsia due to functional disorders (e.g., pyloropasm, cyclic vomiting) or organic disorders, intoxication by infection, dietary or acetonemia.
Patients with intolerance to this drug.
Domperidone should not be used if stimulation of gastric motility might be dangerous, e.g. In the presence of gastrointestinal haemorrhage, mechanical obstruction or perforation. Domperidone is also contraindicated in patients with a prolactin-releasing pituitary tumor (prolactinoma).
Side effects are rarely occured, exceptionally some transient intestinal cramp have been reported.
Extrapyramidal phenomena are rare, and this effect reverse spontaneously and completely as soon as the treatment is stopped.
As the pituitary gland is located outsde the blood-brain barrier, domperidone may induce an increase in the plasma prolactin level.
In rare cases, hyperprolactinaemia may cause neuroendocrinological phenomena, e.g., galactorrheae.
Rare allergic reaction, e.g., rash and urticaria has also been reported.
Nausea and vomiting:
2.5 - 5 mg per 10 kg of body weight or 0.3-0.6 ml/5 kg of bodyweight, 3-4 times daily before meals or before retiring.
WARNING and PRECAUTIONS
If antacids and antisecretion drug are used concomitantly, they should be given after meals and not administered concomitantly with domperidone.
Domperidone is not recommended for long term treatment.
Used with caution in patients with hepatic impairments.
Not recommended in pregnant women or nursing mothers.
Because the metabolic and blood brain barrier function are not fully developed, the possible occurrence of neurological side effects can not be totally excluded in infant < 1 year.
In patients with renal insufficiency, on repeated administration, the dose and frequency should be reduced.
Concomitant administration of anticholinergic drugs may antagonize the antidyspepsia effects of domperidone. Antacids and antisecretory drugs should not be given with domperidone because they may lower the domperidone bioavailability. Theoretically, gastrokinetic effects of domperidone could influence the absorption of concomitant orally administered drugs, especially 'sustained release' or 'enteric coated' formulations. However, in patients already used digoxin or paracetamol concomitant administration of domperidone did not influence the blood level of these drugs. Domperidone can be administered concomitantly with:
Neurologic drugs, with have no potentiation of effects.
Dopaminergic agonists (bromocriptine, L-dopa), whose unwanted peripheral effects e.g. Digestive disorders, nausea and vomiting are suppressed without affecting the central activity.
PRESENTATION and Reg. No
VOMETA Drops: Box of bottle @ 10 ml,
Reg. No. : DKL9605019336A1
ON MEDICAL PRESCRIPTION ONLY.
STORE IN A DRY PLACE, BELOW 30oC, PROTECT FROM LIGHT.
SHAKE WELL BEFORE USE.